Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.

Location

Canton

Facts & figures

  • Type of organization
    Private company
  • Year of foundation
    2023
  • Number of employees in Switzerland
    1-9

Key business

Keep browsing

You may also be interested in